Actuate Therapeutics, Inc. Stock: price and insider trades · United States

Elraglusib is the core of the pipeline. Actuate is studying it across several difficult oncology settings, including metastatic pancreatic adenocarcinoma, certain pediatric sarcomas, and head-and-neck or salivary gland cancers. The company has also reported FDA Fast Track and Orphan Drug designations for pancreatic cancer, which may facilitate regulatory interactions and speed development pathways, although they do not ensure approval or commercial success. Actuate does not yet have a diversified commercial portfolio, so its competitive position remains highly dependent on clinical efficacy signals, tolerability, and the company’s ability to fund ongoing development. ([actuatetherapeutics.com](https://actuatetherapeutics.com/press_releases/actuate-therapeutics-announcesfda-fast-track-designation-for-9-ing-41for-treatment-of-pancreatic-cancer/?utm_source=openai))

Geographically, Actuate is still overwhelmingly U.S.-centric, with R&D activity anchored in the United States and supported by academic and clinical collaborators. The company has also described engagement with key opinion leaders and patient advocacy groups in the U.S., EU, UK, and Japan, suggesting a gradually expanding international footprint, albeit without a broad commercial organization. The company was founded before its 2024 IPO and has been financed through multiple equity raises, a typical profile for a development-stage biotech that remains dependent on capital markets. ([actuatetherapeutics.com](https://actuatetherapeutics.com/wp-content/uploads/2024/09/Actuate-Therapeutics-Corporate-Presentation-January-2026.pdf?utm_source=openai))

Recent developments have been important. In 2025, Actuate reported positive clinical updates for elraglusib, including phase 2 data in metastatic pancreatic cancer and salivary gland cancers, and it announced a collaboration with Incyte Corporation and the University of Pittsburgh for a pancreatic cancer study combining elraglusib, retifanlimab, and mFOLFIRINOX. The company also raised capital during 2025, including a $17.25 million public offering, underscoring both clinical momentum and ongoing financing needs. For investors, ACTU remains a speculative biotech name driven by clinical catalysts, regulatory milestones, and periodic dilution risk. ([actuatetherapeutics.com](https://actuatetherapeutics.com/press_releases/actuate-therapeutics-to-collaborate-with-incyte-corporation-and-the-university-of-pittsburgh-on-clinical-trial-of-elraglusib-in-combination-with-retifanlimab-and-mfolfirinox-in-patients-with-advanced/?utm_source=openai))